trending Market Intelligence /marketintelligence/en/news-insights/trending/hgy7errxxg00h8d349obyg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Principia Biopharma sets price range for IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Principia Biopharma sets price range for IPO

Principia Biopharma Inc. announced the price range for its IPO to list on the Nasdaq Global Market under the ticker PRNB.

The biopharmaceutical company is planning to offer 4,687,500 common shares for anywhere between $15 and $17 apiece.

Principia Biopharma said certain stockholders, including those affiliated with certain of its directors, intend to buy $26 million worth of its stock during the IPO.

Bank of America Merrill Lynch, Leerink Partners LLC, Wells Fargo Securities LLC and Robert W. Baird & Co. Inc. are serving as underwriters for the IPO, which is designed to help Principia Biopharma raise funds for some of its drug candidates, including lead product candidate PRN1008 — a Bruton's tyrosine kinase, or BTK, inhibitor for treating a group of rare skin disorders called pemphigus.

PRN1008 is also being studied as a treatment for immune thrombocytopenic purpura, a disorder that can lead to easy or excessive bruising and bleeding.